Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Correction: Resolutions from the Annual General Meeting of Novo Nordisk A/S

The FDA has issued a Refusal to File letter covering Novo Nordisk A/S' (NYSE: NVO) label expansion application for once-weekly semaglutide 2.0 mg to treat type 2 diabetes, which was filed on 20 January. The FDA has requested additional information in the letter, including data relating to a proposed new manufacturing site.

FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application

Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes which was filed on 20 January 2021. A refusal to file letter is received when the FDA determines additional information is required to review a complete application.

Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

Gilead Sciences

Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.

Gilead (GILD) Expands NASH Collaboration With Novo Nordisk

Abbott Labs

Medtronic

Tandem Diabetes Care

Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.

4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic

Gilead Sciences Inc (NASDAQ: GILD) and Novo Nordisk A/S (NYSE: NVO) have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a Phase 2b study of Novo Nordisk's semaglutide and a fixed-dose combination of Gilead's cilofexor and firsocostat, alone and in combination in people with compensated cirrhosis due to NASH.

Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study

argenx

Biohaven Pharmaceutical Hld

BioMarin Pharmaceutical

Mirati Therapeutics

Novartis

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

7 Pharmaceutical Stocks Working on Their Next Blockbuster

Novo Nordisk is the world's leader in diabetes and obesity care and both diseases are increasing markets. Worldwide obesity has nearly tripled since 1975 and the pandemic has most likely accelerated this negative trend.

Obesity Offers Tremendous Potential For Novo Nordisk

Bagsværd, Denmark, 17 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons on 15 February 2021

Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

Bagsværd, Denmark, 10 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2021

Bagsværd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons on 3-4 February 2021

Novo Nordisk A/S (NVO) CEO Lars Jørgensen on Q4 2020 Results - Earnings Call Transcript

Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of $0.64.

Novo Nordisk: Q4 Earnings Insights

Novo Nordisk A/S (NYSE: NVO) posted better than expected fourth-quarter earnings but said that sales growth was negatively impacted by COVID-19, driven by fewer patients initiating treatment, due to social-distancing regulations. The company also said that for continuing trials, recruitment of new patients is still below pre-coronavirus levels.

Novo Nordisk Shares Gain On Fourth Quarter Earnings Beat, Stock Repurchase Program

Financial report for the period 1 January 2020 to 31 December 2020

Novo Nordisk's net profit increased by 8% in 2020

Con Ed

Hormel Foods

Kimberly-Clark

Verizon

Walgreens

Walmart

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

While stocks keep going up and up, more risks are mounting under the surface. As such, you should be looking at safe stocks to buy now.

7 Safe Stocks to Buy for Solid Returns in Tumultuous Times

Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.

Novo Nordisk (NVO) Files for Ozempic's Label Expansion in US

Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA).

Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

Novo Nordisk is the global leader in obesity and diabetes treatments. There is evidence that the lockdowns increased the number of people suffering from obesity.

Novo Nordisk: Poised To Profit As The Lockdowns Make The Obesity Crisis Worse

Novo Nordisk is a well-managed business with long-term growth opportunities. It is the world market leader in diabetes and obesity care.

Novo Nordisk: An Outstanding Company For The Long Term

Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insurance coverage because of a change in job status due to the pandemic. The company also would like...

Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com

In view of the overheated markets, it is worthwhile to take a look at the not so well-trodden paths. However, investors are facing a dilemma. There are a lot of great companies, but only a small number of good investments.

Best Buys For 2021: Don't Choose The Usual U.S. Suspects, Buy Those European Champions Instead

Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.

News for Novo Nordisk Stock (NVO)